Aligos Therapeutics’ $150 Million Initial Public Offering

Latham & Watkins LLP represented Aligos Therapeutics, Inc., while Davis Polk advised the representatives of the several underwriters in the transaction. Aligos Therapeutics, Inc. has announced…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Author: Ambrogio Visconti

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here